CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1465 · Search date 2026-07-23 · Methodology v0.6

Lactoferrin,
does it really help with Reduced inflammatory and total lesion counts and severity in mild-to-moderate acne?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Mild-to-moderate acne may improve, but lactoferrin alone is not confirmed strongly enough to replace standard treatment
What the
research shows
Oral lactoferrin is rated C because it may reduce inflammatory lesions, total lesion counts, and severity in mild-to-moderate acne. In a 36-person, 12-week double-blind trial, lactoferrin-enriched fermented milk improved inflammatory lesions by 38.6%, total lesions by 23.1%, and acne grade by 20.3% compared with control fermented milk. A 168-person trial was also positive but combined lactoferrin with vitamin E and zinc, preventing isolation of the lactoferrin effect. Small samples or cointerventions and no direct comparison with standard acne therapy limit the finding to a supportive signal.
What the
ads claim
Relative lesion reductions must not be converted into a percentage of patients cured, and results from a vitamin E and zinc combination cannot be assigned wholly to pure lactoferrin. The evidence does not justify delaying treatment for severe nodular or scarring acne.
*

Useful facts when choosing a product

  • Research formulations used fermented milk containing 200 mg lactoferrin or capsules combining lactoferrin with vitamin E and zinc, so commercial supplements cannot be assumed to have identical ingredient purity or dosing.
  • Because lactoferrin is milk derived, people with milk-protein allergy should avoid it; lactose intolerance is more likely to matter for lactose-containing formulations than for purified lactoferrin itself.
  • Oral use can cause abdominal discomfort, nausea, diarrhea, or constipation, and evidence on pregnancy, breastfeeding, and long-term high-dose safety is limited.
  • Widespread inflammatory acne, nodules, cysts, or scarring should prompt dermatologic standard topical or systemic treatment rather than delay with a supplement.
Gap Measurement · Verdict 1465 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Kim and colleagues double-blind randomized 36 patients with acne to fermented milk containing 200 mg lactoferrin or the same fermented-milk control for 12 weeks. Compared with control, the lactoferrin group improved inflammatory lesion count by 38.6%, total lesion count by 23.1%, acne grade by 20.3%, and sebum by 31.1%. Chan and colleagues randomized 168 participants aged 13 to 40 to lactoferrin with vitamin E and zinc or placebo for three months; maximum reductions at week 10 were 28.5% for total lesions, 32.5% for comedones, and 44% for inflammatory lesions. That study tested three ingredients together. Mueller's 43-person open-label single-arm study showed a total-lesion signal, but inflammatory-lesion reduction had p=0.054 and the uncontrolled design was not confirmatory.

02

Why this is classified as C (50)

A 36-person double-blind controlled trial showed improvements in lesion count and severity, and a larger combination trial supported the direction. The ingredient-attributable trial was very small, the larger trial coadministered vitamin E and zinc, and long-term and standard-treatment comparisons are absent. This limited small-trial evidence supports C with 50 points.

Counterpoint. There is room to try lactoferrin as an adjunct in mild-to-moderate acne, but absence of objective lesion reduction after 8 to 12 weeks should prompt a switch to evidence-based treatment.

Rejudgment record. Cross-check applied — Accepted lesion and severity reductions in a 36-person double-blind trial, while applying the C ceiling because the attributable trial was very small and the 168-person supporting trial coadministered vitamin E and zinc. At cross-check the score was lowered to 50 because the direct evidence is a single 36-participant trial and larger trials used zinc and vitamin E combinations, limiting attribution to lactoferrin alone (grade C retained).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced inflammatory acne lesion countCA 36-person trial showed 38.6% improvement, but each group had only 18 participants and the larger trial used vitamin E and zinc.
Reduced total acne lesion countCA small controlled trial showed 23.1% improvement and the combination trial supported the direction, but long-term confirmation is absent.
Improved acne severityCAcne grade improved by 20.3% at 12 weeks, but this came from one small formulation-specific trial.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kim J et al. 2010Twelve-week randomized double-blind fermented-milk-controlled trial18Inadequately reported in the abstract and indexing recordInflammatory and total lesion counts, acne grade, sebum, and skin-surface lipidsCompared with control, inflammatory lesions improved by 38.6%, total lesions by 23.1%, acne grade by 20.3%, and sebum by 31.1%.Pivotal ingredient-specific small randomized trial
Chan H et al. 2017Three-month randomized double-blind placebo-controlled trial164Participation by United Laboratories research and development staffTotal lesions, comedones, inflammatory lesions, and sebumThe lactoferrin, vitamin E, and zinc combination showed maximum placebo-adjusted reductions at week 10 of 28.5% in total lesions, 32.5% in comedones, and 44% in inflammatory lesions.Larger supportive randomized trial limited by cointerventions
Mueller EA et al. 2011Eight-week open-label single-arm exploratory study39Inadequately reported in the abstract and indexing recordInflammatory, noninflammatory, and total lesion countsTotal lesions fell by 22.5%, but the 20.2% inflammatory-lesion reduction had p=0.054 and there was no control group.Exploratory supportive consistency evidence
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-23).

Kim J, Ko Y, Park YK, Kim NI, Ha WK, Cho Y. Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition. 2010;26(9):902-909. PMID: 20692602. DOI: 10.1016/j.nut.2010.05.011.
checked
Chan H, Chan G, Santos J, Dee K, Co JK. A randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of lactoferrin with vitamin E and zinc as an oral therapy for mild to moderate acne vulgaris. Int J Dermatol. 2017;56(6):686-690. PMID: 28369875. DOI: 10.1111/ijd.13607.
checked
Mueller EA, Trapp S, Frentzel A, Kirch W, Brantl V. Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study. Curr Med Res Opin. 2011;27(4):793-797. PMID: 21303195. DOI: 10.1185/03007995.2011.557720.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

Lactoferrin x reduced lesion counts and severity in mild-to-moderate acne Evidence Grade C card
[Chamgap] Lactoferrin x reduced lesion counts and severity in mild-to-moderate acne — Evidence Grade C·50. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/oral-lactoferrin-mild-moderate-acne-lesions-severity/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.